Pharmacokinetics of tilmicosin in equine tissues and plasma.
The macrolide antibiotic tilmicosin has potential for treating bacterial respiratory tract infections in horses. A pharmacokinetic study evaluated the disposition of tilmicosin in the horse after oral (4 mg/kg) or subcutaneous (s.c.) (10 mg/kg) administration. Tilmicosin was not detected in equine plasma or tissues after oral administration at this dose. With s.c. injection, tilmicosin concentrations reached a maximum concentration of approximately 200 ng/mL in the plasma of the horses. Tilmicosin concentrations in plasma persisted with a mean residence time (MRT) of 19 h. Maximum tissue residue concentrations (C(max)) of tilmicosin measured in equine lung, kidney, liver and muscle tissues after s.c. administration were 2784, 4877, 1398, and 881 ng/g, respectively. The MRT of tilmicosin in these tissues was approximately 27 h. Subcutaneous administration of tilmicosin resulted in severe reactions at the injection sites.
Clark
C
C
Department of Biomedical Sciences, Western College of Veterinary Medicine, University of Saskatchewan, Saskatoon, SK, Canada. chris.clark@usask.ca
Dowling
P M
PM
Ross
S
S
Woodbury
M
M
Boison
J O
JO
D000284:Administration, Oral; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism / Q000494:pharmacology*; D019540:Area Under Curve; D005260:Female; D006736:Horses / Q000378:metabolism*; D007279:Injections, Subcutaneous / Q000662:veterinary; D007668:Kidney / Q000378:metabolism; D008099:Liver / Q000378:metabolism; D008168:Lung / Q000378:metabolism; D018942:Macrolides / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism / Q000494:pharmacology*; D018482:Muscle, Skeletal / Q000378:metabolism; D015645:Tylosin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood / Q000378:metabolism / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D018942:Macrolides; C052319:tilmicosin; D015645:Tylosin